TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 7, 2015, Pages 2169-2174

  Balatti, Veronica ^a   Rizzotto, Lara ^a   Miller, Cecelia ^b   Palamarchuk, Alexey ^a   Fadda, Paolo ^a   Pandolfo, Rosantony ^a,c   Rassenti, Laura Z ^d   Hertlein, Erin ^b   Ruppert, Amy S ^b   Lozanski, Arletta ^b   Lozanski, Gerard ^b   Kipps, Thomas J ^d   Byrd, John C ^b   Croce, Carlo M ^a   Pekarsky, Yuri ^a  

^a Department of Molecular Virology Immunology and Medical Genetics ^*  (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

17p deletions; CLL; MiR 3676

Indexed keywords

MICRORNA; MICRORNA 3676; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; ONCOPROTEIN; TCL1A PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BLOOD; CANCER GROWTH; CENTROMERE; CHROMOSOME 11Q; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GERMLINE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; T CELL LEUKEMIA; GENETICS;

MUS MUSCULUS;

GENE DELETION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923197477     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500010112     Document Type: Article

References (40)

1. Sgambati M, Linet M, Devesa S (2001) Chronic Lymphocytic Leukemia, Epidemiological, Familial, and Genetic Aspects. Chronic Lymphocytic Leukemias, Second Edition, Revised and Expanded, ed Cheson B (Marcel Dekker, New York) pp. 33-62.
2. Edelmann J, et al. (2012) High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24):4783-4794.
3. Döhner H, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910-1916.
4. Calin GA, et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524-15529.
5. Calin GA, et al. (2008) MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 105(13):5166-5171.
6. Pekarsky Y, et al. (2006) Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66(24):11590-11593.
7. Visone R, et al. (2011) miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118(11):3072-3079.
8. Pekarsky Y, Zanesi N, Croce CM (2010) Molecular basis of CLL. Semin Cancer Biol 20(6): 370-376.
9. Herling M, et al. (2006) TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20(2):280-285.
10. Teitell MA (2005) The TCL1 family of oncoproteins: Co-activators of transformation. Nat Rev Cancer 5(8):640-648.
11. Bichi R, et al. (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99(10):6955-6960.
12. Efanov A, et al. (2010) CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 24(5): 970-975.
13. Yan XJ, et al. (2006) B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 103(31):11713-11718.
14. Enzler T, et al. (2009) Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 114(20):4469-4476.
15. Sánchez-Beato M, Sánchez-Aguilera A, Piris MA (2003) Cell cycle deregulation in B-cell lymphomas. Blood 101(4):1220-1235.
16. Scielzo C, et al. (2010) HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 116(18):3537-3546.
17. Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y (2012) Novel insights in molecular mechanisms of CLL. Curr Pharm Des 18(23):3363-3372.
18. Pekarsky Y, et al. (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 97(7):3028-3033.
19. Pekarsky Y, et al. (2008) Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 105(50):19643-19648.
20. Palamarchuk A, et al. (2012) Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 109(7):2555-2560.
21. Claus R, et al. (2014) Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 124(1):42-48.
22. Ryu S, et al. (2011) Discovery of novel human breast cancer microRNAs from deep sequencing data by analysis of pri-microRNA secondary structures. PLoS ONE 6(2): e16403.
23. Claus R, et al. (2012) Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 30(20):2483-2491.
24. Santanam U, et al. (2010) Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 107(27):12210-12215.
25. Cimmino A, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102(39):13944-13949.
26. Ozsolak F, et al. (2008) Chromatin structure analyses identify miRNA promoters. Genes Dev 22(22):3172-3183.
27. Borchert GM, Lanier W, Davidson BL (2006) RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13(12):1097-1101.
28. Canella D, Praz V, Reina JH, Cousin P, Hernandez N (2010) Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells. Genome Res 20(6):710-721.
29. Richard P, Manley JL (2009) Transcription termination by nuclear RNA polymerases. Genes Dev 23(11):1247-1269.
30. Stilgenbauer S, Zenz T (2010) Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2010:481-488.
31. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88(9):803-816.
32. Trbusek M, Malcikova J (2013) TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 792:109-131.
33. Gunn SR, et al. (2008) Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 10(5):442-451.
34. Haussecker D, et al. (2010) Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA 16(4):673-695.
35. Lee YS, Shibata Y, Malhotra A, Dutta A (2009) A novel class of small RNAs: tRNAderived RNA fragments (tRFs). Genes Dev 23(22):2639-2649.
36. Liu J, et al. (2014) Loss of p53 and altered miR15-a/16-1 MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28(1):118-128.
37. Burger JA, Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592-601.
38. Ponader S, et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-1189.
39. Calin GA, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353(17):1793-1801.
40. Allegra D, et al. (2014) Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. Leukemia 28(1):98-107.